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Abstract
Uterine cervical cancer screening using the 
Bethesda system was put into use in Niigata 
Prefecture in 2010. However, the effectiveness of 
the screening using the Bethesda system has not 
been well evaluated. We aimed to compare the 
results of smears diagnosed using the Bethesda 
system in 2010 with the results of smears 
diagnosed using the Nichibo classification from 
1995 through 2009. A total of 337,029 women 
were screened for cancer. The diagnoses obtained 
using the Bethesda system (18,449 examinees) 
were compared with those obtained using the 
Nichibo classification at the period of 15 years 
(318,580 examinees). The rate of abnormalities 
and the detection rate of dysplasia were displayed 
significant difference between Nichibo 
classification and Bethesda system (p<0.05). 
However, no significant difference was found in 
the cancer detection rate between the two 
classification methods. This finding shows that 
the Bethesda system is useful for the early 
detection of dysplasia such as precursor lesions of 
the uterus and in early treatment.
Introduction
Cytological diagnosis in uterine cervical cancer 
screening has been carried out using a cytological 
classification based on the Nichibo classification 
created by the Japan Association of Obstetricians 
and Gynecologists in 1978 [1]. The Nichibo 
classification categorizes disease into 5 stages 
from Class I to V according to the degree of 
cellular atypia and describes the typical lesion 
and handling method for each class [2]. For this 
reason, the classification was very convenient 
both for clinicians and cytologists. However, the 
Nichibo classification had no standardized 
definition of sample collection method, and of the 
handling of the cells when they were difficult to 
diagnose because of small amount of the samples 
[3]. For this reason, there was a chance to produce 
a false-negative result in case of insufficient 
volume of the cells.  Furthermore, since human 
papilloma virus (HPV) infection has been shown 
to be a risk factor for uterine cervical cancer, the 
categorization and diagnosis of HPV-infected 
cells should be clarified [4].
To solve these problems, in 2008, the Japan 
Association of Obstetricians and Gynecologists 
formally adopted the cytological-diagnosis 
narrative form of the Bethesda system and 
announced the information to gynecologists all 
over the country [5]. The Bethesda system is a 
diagnostic system developed by the National 
Cancer Institute in Bethesda, Maryland, U.S.A., 
in order to solve the problems in the past class 
divisions [6,7]. The features of this system 
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included the description of presumed pathological 
change, the judging of specimens as appropriate 
or inappropriate, and the determination of new 
criteria for dysplastic cells that are difficult to 
diagnose [8]. A comparison of the narrative form 
of the Bethesda system with the Nichibo 
classification is shown in Table 1. The use of this 
narrative form is spreading quickly throughout 
Japan.
In Niigata prefecture, the use of the Bethesda 
system for uterine cervical cancer screening was 
begun in 2010. Because the Bethesda system was 
introduced only recently, its effectiveness has not 
been sufficiently evaluated yet [9-11]. The 
purpose of this research was to compare the 
results of smears performed in uterine cervical 
cancer screenings diagnosed using the Bethesda 
system in 2010 with those diagnosed using the 
Nichibo classification in Niigata Prefecture for 15 
years from 1995 to 2008.
Methods
1. Examinees
The uterine cervical cancer screening was 
carried out in 337,029 women aged 30 years or 
older from 1995 to 2007 (287,658) or aged 20 
years or older from 2008 to 2010 (49,371). The 
subjects underwent the screening every year 
between 1995 and 2007, or every other year 
between 2008 and 2010. The screening was 
carried out among residents of Niigata Prefecture 
by the Niigata Health Service Center.
2. Screening findings and statistical procedures
The results of smears of the uterine cervix 
diagnosed using the Bethesda system in 2010 
were compared with those diagnosed using the 
Nichibo classification from 1995 to 2009. When 
smears of atypical squamous cells of 
undetermined significance (ASC-US), atypical 
squamous cells that cannot exclude high-grade 
squamous intraepithelial lesion (ASC-H), low-
grade squamous intraepithelial lesion (LSIL), 
high-grade squamous intraepithelial lesion 
(HSIL), and squamous cell carcinoma (SCC) 
were found using the Bethesda system, or smears 
of class IIIa, IIIb, IV, and V were found using the 
Nichibo classification, we judged them to be 
“abnormalities.”
The statistical procedures were performed 
using a software system (IBM SPSS Statistics 20, 
USA). We used a χ2-test to reveal the differences 
in the detection rates of examinees requiring 
detailed examination, those diagnosed with 
dysplasia, and those diagnosed with cancer. P 
Table 1. Comparison of the Bethesda system and the Nichibo classification
Bethesda system Nichibo classification
Classification Notation
Screening
findings1)
Classification
Screening
findings1)
Negative for intraepithelial lesion or malignancy NILM Normal I or II Normal
Atypical squamous cells of undetermined significance ASC-US Abnormal
II Normal
IIIa Abnormal
Atypical squamous cells cannot exclude HSIL ASC-H Abnormal IIIa or IIIb Abnormal
Low grade squamous intraepithelial lesion LSIL Abnormal IIIa Abnormal
High grade intraepithelial lesion HSIL Abnormal IIIa or IIIb or IV Abnormal
Squamous cell carcinoma SCC Abnormal V Abnormal
1) The following smears were categorized as “abnormal”: ASC-US and over by Bethesda system, and 
class IIIa and over by Nichibo classification
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values of less than 0.05 were considered to be 
statistically significant.
Results
Table 2 shows the results of uterine cervical 
cancer screening by year from 1995 to 2010. The 
rates of abnormalities in 2010 and in the past 15 
years were 1.43% (264/18,449) and 0.43% 
(1381/318,580), respectively. The rate of 
abnormalities was displayed significant difference 
between Nichibo classification and Bethesda 
system (p<0.05).
Table 3 shows the results of the uterine cervical 
cancer screening by classification method. 
Number of examinees having screened as 
abnormalities were 131 in 2010 and 546 in past 
15 years. The detection rate of examinees 
diagnosed with dysplasia using the Bethesda 
system was 0.71% (131 examinees) and that 
found using the Nichibo classification was 0.17% 
(546 examinees). The detection rate obtained 
using the Bethesda system was 4.2 times higher 
than that obtained using the Nichibo 
classification. The dictation rate of dysplasia of 
initial  examinees is higher than re-examinees in 
the both of Nichibo classification and Bethesda 
system (p<0.025).
The rate of examinees diagnosed with cancer 
Table 2. Results of cytology by year, and by either Nichibo classification or Bethesda system
Classification Year
Number of
examinees1)
Number of
abnormalities2) (%)
Nichibo 
classification
1995 26,131 68 (0.26)
1996 26,820 42 (0.16)
1997 25,039 69 (0.28)
1998 23,495 53 (0.23)
1999 21,935 55 (0.25)
2000 22,295 74 (0.33)
2001 24,014 63 (0.26)
2002 23,210 83 (0.36)
2003 24,406 135 (0.55)
2004 23,450 103 (0.44)
2005 16,751 88 (0.53)
2006 16,354 114 (0.70)
2007 13,758 109 (0.79)
2008 14,335 132 (0.92)
2009 16,587 193 (1.16)
Subtotal  318,580 1,381 (0.43)
Bethesda system 2010 18,449 264 (1.43)
Total 337,029 1,645 (0.49)
1)  Examinees were consisting of initial examinees and re-examinees.
2)   The following smears were categorized as “abnormalities”: class IIIa and over by Nichibo 
classification from 1995 to 2009, and ASC-US and over by Bethesda system in 2010.
    *: p<0.05
*
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was 0.08% using the Bethesda system. And no 
significant difference was found compared with 
0.08% in the Nichibo classification.
Discussion
In this study, we found a significant increase in 
the detection rates of abnormalities or diagnosed 
with dysplasia in uterine cervical cancer screening 
using the Bethesda system. However, no 
significant difference was found in the cancer 
detection rate between the two classifications.
In the Nichibo classification, examiners 
working for the Niigata Health Service Center 
were allowed to determine the degree of HPV-
infected cells by themselves. On the other hand, 
the Bethesda system accepts evidence of the 
development of uterine cervical cancer by HPV 
infection. HPV-infected cells were categorized as 
the LSIL, and difficult cells to judge were 
categorized as ASC-US. People diagnosed with 
LSIL and ASC-US were categorized as 
examinees requiring detailed examination. These 
two factors seem to have increased the detection 
rate of examinees requiring detailed examination 
in the Bethesda system.
The detection rate of examinees diagnosed 
with dysplasia showing precursor lesions was 
higher in the Bethesda system than the Nichibo 
classification. This may simply depend on the 
increase in the number of examinees requiring 
detailed examination in the Bethesda system. 
However, no significant difference was found in 
the cancer detection rate between the Bethesda 
system and the Nichibo classification. 
Furthermore, no significant difference was found 
in the cancer detection rate between the initial 
examinees and the re-examinees by the two 
classification methods.
Women diagnosed as abnormalities by the 
screening then visit a clinic or a general hospital, 
and then receive a routine follow-up. Once a 
woman is diagnosed as dysplasia or more, she 
does not undergo the cancer screening again. For 
this reason, there may be no significant difference 
in the cancer detection rate between the two 
classification methods. The purpose of the cancer 
screening is to find precursor lesions early so that 
effective early treatment can be administered. 
From this standpoint, the Bethesda system is 
more valuable than the Nichibo classification in 
uterine cervical cancer screening.
Some limitations in the present study should be 
mentioned. We were unable to obtain results for 
the same samples diagnosed by the Nichibo 
Table 3. Results of uterine cervical cancer screening by the two classification methods
Screening findings Clinical diagnosis
Classification
Number of
examinees
Number of
abnormalities1) (%)
Number of
dysplasia cases (%)
Number of
cancer cases (%)
Nichibo
classification
Initial examinees 60,215 751 (1.25) 310 (0.51) 167 (0.28)
Re-examinees 258,365 630 (0.24) 236 (0.09) 84 (0.03)
Total 318,580 1,381 (0.43) 546 (0.17) 251 (0.08)
Bethesda
system
Initial examinees 6,383 168 (2.63) 81 (1.27) 12 (0.19)
Re-examinees 12,066 96 (0.80) 50 (0.41) 2 (0.02)
Total 18,449 264 (1.43) 131 (0.71) 14 (0.08)
1)   The following smears were categorized as “abnormalities”: class IIIa and over by Nichibo classification, and ASC-US 
and over by Bethesda system.
    *1: p<0.025
    *2: p<0.05
    n.s.: not significant
*1
*1
*2 n.s.
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classification. Therefore, we were unable to make 
a direct comparison between results obtained 
using the Bethesda system and those obtained 
with the Nichibo classification. By comparing the 
results diagnosed by the two classifications using 
the same samples, the usefulness of the Bethesda 
system may be clarified. The age of the examinees 
was 30 years and older from 1995 to 2007, and it 
was 20 years and older in those examined in 2008 
and later. To determine whether the differences in 
the results were influenced by the difference in 
the age of the examinees, the results obtained in 
2010 were compared with those obtained between 
2008 and 2009. The mean detection rate of 
examinees requiring detailed examination was 
1.43% (264/18,449) in 2010, while it was 1.05% 
(325/30,922) in 2008 and 2009. The difference 
between the 1.43% and 1.05% was a significant 
difference (p<0.05). This result demonstrated the 
usefulness of the Bethesda system in assessing 
results obtained from women aged 20 years and 
older.
In summary, we observed an increase in the 
detection rates of abnormalities n and in those 
diagnosed with dysplasia using the Bethesda 
system in uterine cervical cancer screening. This 
system can detect precursor lesions of the uterus 
at an early stage. While our findings require 
further confirmation using the same samples, we 
demonstrate the usefulness of the Bethesda 
system in uterine cervical cancer screening.
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